{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020123","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.176482+00:00","generated_at":"2026-06-05T14:58:59.854912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated","bullets":["Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).","Revenue $1.7M from Ono collaboration preclinical activities; no product revenue.","FT522 (CAR NK) first patient treated; Phase 1 includes ADR technology, regimen with/without chemo conditioning.","FT825/ONO-8250 (CAR T) Phase 1 started for solid tumors; HER2-targeted with novel synthetic controls.","CIRM awarded $7.9M grant for FT819 Phase 1 SLE study; study start-up at multiple U.S. sites."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020123","json":"https://secwatch.observer/filing/0000950170-24-020123.json","markdown":"https://secwatch.observer/filing/0000950170-24-020123.md","text":"https://secwatch.observer/filing/0000950170-24-020123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/0000950170-24-020123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/fate-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:58:59.854912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7dac103d87965a006d321efc98d11db98e5b268","claim":"FATE THERAPEUTICS INC reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 26, 2024, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/0000950170-24-020123-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}